Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

Exosome Diagnostics, Lilly ink collaboration
November 2013
SHARING OPTIONS:

NEW YORK—Exosome Diagnostics and Eli Lilly and Co. have inked a collaboration agreement to discover and validate biomarkers through the use of Exosome Diagnostics’ proprietary EXO50 nucleic acid extraction kit. The agreement grants Lilly early access to Exosome Diagnostics technology for identifying key gene mutations and expression levels in blood that may relate to drug response and disease recurrence. No financial details were disclosed.
 
“Exosome Diagnostics technology may provide a unique opportunity to gain insight into the biology of complex conditions such as cancer and immune disorders,” said Andrew Schade, senior medical director, diagnostic and experimental pathology at Lilly. “Exosome technology enables biofluid molecular sampling and the ability to monitor disease progression in real time. As Lilly explores new ways to pursue patient tailoring, we'll continue to work with partners to expand our capabilities.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.